-
-
-
Vice Chairman of Celltrion
Kim Hyoung-ki
Led the Birth of Korea’s First KRW 1 Trillion Drug, Driving Celltrion’s Global Growth
-
Last Updated on Mar 18, 2025
Kim Hyoung-ki is the Vice Chairman and CEO of Celltrion.
He is focused on securing a strong foothold in overseas markets for "Remsima SC," a biosimilar for autoimmune diseases.
He was born on May 3, 1965, in Dangjin, Chungnam.
He graduated from Suwon High School and earned a degree in political science and diplomacy from Sogang University. He later completed an MBA program at the University of Michigan's Ross School of Business.
He began his career at Daewoo Motors, where he worked as the head of the strategic planning team.
When Seo Jung-jin founded Nexol, the predecessor of Celltrion, Kim joined the company and held key roles such as head of strategic planning, chief of staff, and head of corporate planning and coordination.
He served as Senior Executive Vice President and President of Celltrion before becoming Co-CEO. Later, he was appointed Vice Chairman and CEO of Celltrion Healthcare, a Celltrion subsidiary.
Following the merger of Celltrion and Celltrion Healthcare, he became Vice Chairman and CEO of the newly integrated Celltrion's Global Business Division.
He is known as one of Chairman Seo Jung-jin’s most trusted and closest aides.
At Celltrion, he effectively acted as the Chief Financial Officer (CFO) and played a key role in leading the company's transfer to the KOSPI stock exchange.
He is widely regarded as "Chairman Seo's shield" for his proactive handling of various accounting-related controversies.
#Celltrion #KimHyoungki #biosimilars #pharmaceuticals #RemsimaSC #businessleadership #finance #Korea #SeoJungjin #CFO